
Caio Jcs Fernandes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4747134/publications.pdf Version: 2024-02-01



FEDN

#	Article	IF	CITATIONS
1	Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis. Circulation, 2009, 119, 1518-1523.	1.6	176
2	Cancer-associated thrombosis: the when, how and why. European Respiratory Review, 2019, 28, 180119.	7.1	160
3	Survival in Schistosomiasis-Associated Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2010, 56, 715-720.	2.8	68
4	NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respiratory Medicine, 2007, 101, 69-75.	2.9	65
5	Pulmonary Arterial Hypertension in the Southern Hemisphere. Chest, 2015, 147, 495-501.	0.8	54
6	The Role of Target Therapies in Schistosomiasis-Associated Pulmonary Arterial Hypertension. Chest, 2012, 141, 923-928.	0.8	48
7	Skeletal Muscle Abnormalities in Pulmonary Arterial Hypertension. PLoS ONE, 2014, 9, e114101.	2.5	41
8	Quality of life as a prognostic marker in pulmonary arterial hypertension. Health and Quality of Life Outcomes, 2014, 12, 130.	2.4	40
9	Schistosomiasis associated pulmonary hypertension. International Journal of Clinical Practice, 2010, 64, 25-28.	1.7	27
10	Schistosomiasis and pulmonary hypertension. Expert Review of Respiratory Medicine, 2011, 5, 675-681.	2.5	27
11	New anticoagulants for the treatment of venous thromboembolism. Jornal Brasileiro De Pneumologia, 2016, 42, 146-154.	0.7	27
12	Other Causes of PAH (Schistosomiasis, Porto-Pulmonary Hypertension and Hemolysis-Associated) Tj ETQq0 0 0	rgB <u>T</u> (Ove	rlock 10 Tf 50
13	Pulmonary arterial hypertension in schistosomiasis. Current Opinion in Pulmonary Medicine, 2016, 22, 408-414.	2.6	20
14	Tomographic findings of acute pulmonary toxoplasmosis in immunocompetent patients. BMC Pulmonary Medicine, 2014, 14, 185.	2.0	19
15	Left ventricular dysfunction in patients with suspected pulmonary arterial hypertension. Jornal Brasileiro De Pneumologia, 2014, 40, 609-616.	0.7	18
16	Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension. BMC Pulmonary Medicine, 2015, 15, 118.	2.0	16
17	Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era. European Respiratory Journal, 2018, 51, 1800307.	6.7	16
18	Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension. International Journal of Clinical Practice, 2007, 61, 153-156	1.7	13

Journal of Clinical Practice, 2007, 61, 153-156.

CAIO JCS FERNANDES

#	Article	IF	CITATIONS
19	Clinical response to sildenafil in pulmonary hypertension associated with Gaucher disease. Journal of Inherited Metabolic Disease, 2005, 28, 603-605.	3.6	11
20	Mechanisms of Exercise Limitation and Prevalence of Pulmonary Hypertension in Pulmonary Langerhans Cell Histiocytosis. Chest, 2020, 158, 2440-2448.	0.8	11
21	Outcomes and prognostic factors of decompensated pulmonary hypertension in the intensive care unit. Respiratory Medicine, 2021, 190, 106685.	2.9	11
22	Pólipo traqueal. Jornal Brasileiro De Pneumologia, 2007, 33, 616-620.	0.7	10
23	Selectins and Platelet-Derived Growth Factor (PDGF) in Schistosomiasis-Associated Pulmonary Hypertension. Lung, 2014, 192, 981-986.	3.3	9
24	Reperfusion in acute pulmonary thromboembolism. Jornal Brasileiro De Pneumologia, 2018, 44, 237-243.	0.7	9
25	Extended anticoagulation after venous thromboembolism: should it be done?. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661987855.	2.6	9
26	Carbon monoxide diffusing capacity and the complexity of diagnosis in pulmonary arterial hypertension. European Respiratory Journal, 2014, 43, 963-965.	6.7	8
27	Challenging the concept of adding more drugs in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1701527.	6.7	7
28	Use of thrombolytic agents in the treatment of acute pulmonary thromboembolism: things are not as simple as you might think. Jornal Brasileiro De Pneumologia, 2019, 45, e20180297.	0.7	7
29	Evolution in the management of non-small cell lung cancer in Brazil. Jornal Brasileiro De Pneumologia, 2017, 43, 403-404.	0.7	6
30	Atualização no Tratamento da Hipertensão Arterial Pulmonar. Arquivos Brasileiros De Cardiologia, 2021, 117, 750-764.	0.8	6
31	Inhaled iloprost as third addâ€on therapy in idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-3.	1.7	4
32	Pulmonary Hypertension in General Cardiology Practice. Arquivos Brasileiros De Cardiologia, 2019, 113, 419-428.	0.8	4
33	Goal-oriented treatment of pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2014, 20, 409-413.	2.6	3
34	Moving forward for incidental pulmonary embolism in cancer patients. European Respiratory Journal, 2021, 58, 2004630.	6.7	3
35	Lung Cavities in Chronic Thromboembolic Pulmonary Hypertension. Clinics, 2020, 75, e1373.	1.5	3
36	Brazilian Thoracic Society recommendations for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension. Jornal Brasileiro De Pneumologia, 2020, 46, e20200204.	0.7	3

CAIO JCS FERNANDES

#	Article	IF	CITATIONS
37	Schistosomiasis and Pulmonary Hypertension. Progress in Respiratory Research, 2012, , 143-148.	0.1	2
38	Differential cellular FGF-2 upregulation in the rat facial nucleus following axotomy, functional electrical stimulation and corticosterone: a possible therapeutic target to Bell's palsy. Journal of Brachial Plexus and Peripheral Nerve Injury, 2014, 05, e82-e96.	1.0	2
39	Should all COVID-19 patients be approached in the same way?. Jornal Brasileiro De Pneumologia, 2020, 46, e20200218-e20200218.	0.7	1
40	Thrombolysis in acute pulmonary embolism. Revista Da Associação Médica Brasileira, 2020, 66, 263-267.	0.7	1
41	Prognostic value of predicted 6MWD in PAH. , 2015, , .		Ο
42	Effect of targeted therapies on survival of schistosomiasis associated pulmonary arterial hypertension. , 2017, , .		0